JMP Securities Maintains Market Outperform on Mirati Therapeutics, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan maintains a Market Outperform rating on Mirati Therapeutics (NASDAQ:MRTX) and raises the price target from $58 to $82.
October 06, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities maintains a Market Outperform rating on Mirati Therapeutics and raises the price target from $58 to $82.
The news of JMP Securities maintaining a Market Outperform rating and raising the price target for Mirati Therapeutics is likely to have a positive impact on the company's stock. This is because it signals the analyst's confidence in the company's future performance, which could encourage investors to buy the stock, potentially driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100